The present invention relates to a pharmaceutical combination for use in the treatment of squamous cell carcinoma, comprising a CDK inhibitor selected from the compounds of formula (I) or a pharmaceutically acceptable salt thereof and one or more antineoplastic agents agents selected from sorafenib, lapatinib, erlotinib, cisplatin, 5-fluorouracil , docetaxel or cetuximab or a pharmaceutically acceptable salt thereof. The said pharmaceutical combination exhibits synergy when used in the treatment of squamous cell carcinoma. The invention also relates to pharmaceutical composition comprising the said combination and a method for the treatment of squamous cell carcinoma, using a therapeutically effective amount of said combination.本發明關於一種用於治療鱗狀細胞癌的藥物組合物,包含選自結構式(I)化合物的一CDK抑制劑或一其藥學上可接受之鹽類,以及選自索拉非尼、拉帕替尼、埃羅替尼、順鉑、5-氟尿嘧啶、多西紫杉醇或西妥昔單抗的一或更多抗惡性腫瘤劑或一其藥學上可接受之鹽類。該所述藥物組合物當使用治療鱗狀細胞癌時表現加乘效果。本發明亦關於包含該所述組合物的藥物組成分以及用於治療鱗狀細胞癌的方法,其使用一治療上有效量之所述組合物。Detroit-562...細胞μM...微米
